The FIRSTT Study: Comparing Focused Ultrasound and Uterine Artery Embolization for Uterine Fibroids
25 Years
N/A
Female
Symptomatic Uterine Leiomyomas, Fibroids, Uterine Fibroids, Myomas
Trial Information
The FIRSTT Study: Comparing Focused Ultrasound and Uterine Artery Embolization for Uterine Fibroids
Uterine fibroids affect up to 70 to 80% of women and about 30% of women are symptomatic.
Over 200,000 hysterectomies are performed each year for uterine fibroids in the USA. The
direct health care costs attributable to uterine fibroids exceed $2.1 billion annually.
Fibroids are reported to cause a number of symptoms including heavy or prolonged menstrual
bleeding, pelvic pressure, pain with menses and bowel and bladder dysfunction. However,
fibroid symptomatology is incompletely understood. Understanding and addressing the myomas
pain are important in optimizing treatment outcomes and controlling health care costs from a
societal perspective. This study proposes to optimally characterize symptoms and symptom
relief in women with leiomyomas severe enough to seek interventional therapy. Secondly we
will characterize a variety of symptoms utilizing standardized instruments for other pelvic
diseases and symptoms to optimize comparisons with other disease processes.
Clinical and scientific significance of the studies is high. We look to generate resources
which can be used at a later time to assess the biologic and genetic variables affecting
treatment outcome and to comprehensively assess the societal economic impact of uterine
fibroids and their treatment with UAE and MRgFUS.
Participants will be in the study for up to 36 months following fibroid treatment.
Inclusion Criteria:
1. Women able to give informed consent and willing and able to attend all study visits
2. Premenopausal women at least 25 years of age
3. No evidence of High Grade SIL by pap smears or HPV testing within institutional
guidelines.
Exclusion Criteria:
1. Women actively trying for pregnancy or currently pregnant
2. Uterine size > 20 weeks
3. Prior myomectomy, UAE, or MRgFUS. Previous hysteroscopic or laparoscopic myomectomy
for the removal of only pedunculated leiomyomas (as described in #17, below) will be
allowed and evaluated on an individual basis to determine eligibility for treatment.
4. More than 6 fibroids > than 3 centimeters in maximal diameter
5. Allergy to either gadolinium or iodinated contrast
6. Implanted metallic device prohibiting MRI
7. Severe claustrophobia
8. BMI which prohibits subject from fitting in MRI device
9. Severe abdominal scarring precluding safe MRgFUS treatment
10. Active pelvic infection
11. Intrauterine contraceptive device in place at the time of treatment
12. Current use of GnRH agonists or antagonists
13. Unstable medical conditions requiring additional monitoring during the procedure
14. Bleeding diathesis requiring medical treatment
15. Imaging suggestive of malignant disease of uterus, ovary, or cervix
16. Imaging suggestive of only adenomyosis
17. Pedunculated submucosal or subserosal myoma with a stalk less than 25% of the maximal
fibroid diameter
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Symptomatic outcomes measured by validated instruments
Outcome Time Frame:
At baseline, 6 weeks and 6, 12, 24, and 36 months following treatment.
Safety Issue:
No
Principal Investigator
Elizabeth A. Stewart, M.D.
Investigator Role:
Principal Investigator
Investigator Affiliation:
Mayo Clinic
Authority:
United States: Institutional Review Board
Study ID:
09-005095
NCT ID:
NCT00995878
Start Date:
October 2009
Completion Date:
December 2015
Related Keywords:
- Symptomatic Uterine Leiomyomas
- Fibroids
- Uterine Fibroids
- Myomas
- Uterine fibroids
- Fibroids
- Uterine leiomyomas
- UAE
- UFE
- Magnetic resonance guided focused ultrasound
- MRgFUS
- Pelvic pain
- Leiomyoma
- Myofibroma
- Myoma
Name | Location |
|---|---|
| Mayo Clinic | Rochester, Minnesota 55905 |
| Duke University Health System | Durham, North Carolina 27705 |
